What is Rejoni?
Rejoni, Inc., founded in June 2020 and based in Bedford, MA, is dedicated to advancing women's health through the development and commercialization of innovative gynecological products. The company leverages proprietary biomaterials to create solutions aimed at addressing unmet needs within the sector. This strategic financing round is expected to fuel Rejoni's growth and market penetration.
How much funding has Rejoni raised?
Rejoni has raised a total of $65M across 3 funding rounds:
Series A
$15M
Series B
$25M
Other Financing Round
$25M
Series A (2020): $15M with participation from Delos Capital, Ascension Ventures, and Sparta Group
Series B (2022): $25M led by Catalyst Health Ventures, Iyengar Capital Partners, Sparta Group, Delos Capital, Ascension, and Amed Ventures
Other Financing Round (2026): $25M supported by Catalyst Health Ventures, Ascension Ventures, Amed Ventures, Sparta Group, Delos Capital, ClavystBio, FemHealth Ventures, and Iyengar Capital Partners
Key Investors in Rejoni
Catalyst Health Ventures
Catalyst Health Ventures is a venture capital firm focused on investing in transformative medical technologies that address global unmet healthcare needs, providing capital and strategic insight to MedTech entrepreneurs.
Sparta Group
Sparta Group is an industry-leading contractor with over 25 years of experience in the construction industry, providing clients with solution-based services and overcoming difficult problems in commercial and industrial buildings.
Delos Capital
Delos Capital is a private equity firm based in New York City that specializes in private investment and financial advisory services, focusing on complex transactions and providing tailored solutions.
What's next for Rejoni?
With a substantial enterprise-level funding context, Rejoni is poised for significant scaling and product commercialization. The recent strategic investment suggests a focus on expanding market reach and potentially further research and development into its proprietary biomaterial technology. Future endeavors will likely involve navigating regulatory pathways and establishing robust distribution channels to bring its gynecological products to a wider audience.
See full Rejoni company page
